NBIX – neurocrine biosciences, inc. (US:NASDAQ)
Stock Stats
News
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its price target raised by analysts at Citigroup Inc. from $140.00 to $150.00. They now have a "neutral" rating on the stock.
Neurocrine Biosciences Presented CAHtalyst™ Pediatric Study Baseline Characteristics and CAHtalog™ Registry Data at PES 2024 [Yahoo! Finance]
Neurocrine Biosciences Presented CAHtalyst™ Pediatric Study Baseline Characteristics and CAHtalog™ Registry Data at PES 2024
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its price target raised by analysts at Canaccord Genuity Group Inc. from $154.00 to $164.00. They now have a "buy" rating on the stock.
Form 10-Q NEUROCRINE BIOSCIENCES For: Mar 31
Form 8-K NEUROCRINE BIOSCIENCES For: May 01
Form 4 NEUROCRINE BIOSCIENCES For: Apr 15 Filed by: BENEVICH ERIC
Form 144 NEUROCRINE BIOSCIENCES Filed by: BENEVICH ERIC
Form ARS NEUROCRINE BIOSCIENCES For: Dec 31
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.